

	baseline phase			12 week short-term phase (S)					12 months long-term phase (L)				End of Study Visit	
Planned Study Day	-42 to -16	-15	- 14 to -1	1	15	56	83	84	175	267	358	449	450	
Visit	Screening	P0	2 sessions of diabetes education	S1	S2*	S3	S4	P1	L1	L2	L3	L4	P2	
Screening information, informed consent	D													
Screening, inclusion/exclusion criteria	D													
Blood-sample (HbA1c)	D			D			D		D	D	D	D		
Blood-sample (liver enzymes, other endocr. parameters)	D			D					D			D		
Treatment preference		P												
CES-D questionnaire	D			D			D		D	D	D	D		
Diagnosis information, informed consent	D													
Other questionnaires		P						P					P	
Hamilton Rating Scale (HAM-D-17)		P						P					P	
SCID-Interview		P											P	
Review mental disorder related inclusion/exclusion criteria		P												
Treatment information, informed consent		P		D										
Randomisation				D										
CBT group: Cognitive behavioural therapy				<b>10 sessions P</b>										
Sertraline group: Delivery of medication				D	D	D	D		D	D	D	D		
Sertraline group: Blood-sample (plasma concentrations of sertraline)						D	D		D	D	D	D		
Diabetological treatment as usual	D			D			D		D	D	D	D		
Dose adjustment insulin/sertraline				optional supplementary visits in case of problems with diabetological treatment or side-effects of sertraline D										
Recording and monitoring of adverse events				continuously D, P										
Recording of concomitant medication			continuously D											
Review inclusion/exclusion criteria			continuously D, P											